Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (vcu-art2) pilot study]

American Journal of Cardiology

Volumn 111, Issue 10, 2013, Pages 1394-1400

  Abbate, Antonio ^a   Van Tassell, Benjamin Wallace ^a   Biondi Zoccai, Giuseppe ^b   Kontos, Michael Christopher ^a   Grizzard, John Dallas ^a   Spillman, Debra Whittaker ^a   Oddi, Claudia ^a   Roberts, Charlotte Susan ^a   Melchior, Ryan David ^a   Mueller, George Herman ^a   Abouzaki, Nayef Antar ^a   Rengel, Lenore Rosemary ^a   Varma, Amit ^a   Gambill, Michael Lucas ^a   Falcao, Raquel Appa ^a   Voelkel, Norbert Felix ^a   Dinarello, Charles Anthony ^c   Vetrovec, George Wayne ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; INFECTION; INJECTION SITE PAIN; MALE; OUTCOME ASSESSMENT; PARAMETERS; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALS, UNIVERSITY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR REMODELING; VIRGINIA;

EID: 84876981024     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.01.287     Document Type: Article

References (20)

1. N.G. Frangogiannis Regulation of the inflammatory response in cardiac repair Circ Res 110 2012 159 173
2. E. Mezzaroma, S. Toldo, D. Farkas, I.M. Seropian, B.W. Van Tassell, F.N. Salloum, H.R. Kannan, A.C. Menna, N.F. Voelkel, and A. Abbate The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Proc Natl Acad Sci U S A 108 2011 19725 19730
3. C.A. Dinarello Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 2011 3720 3732
4. C.A. Dinarello, A. Simon, and J.W. van der Meer Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Nat Rev Drug Discov 11 2012 633 652
5. A. Abbate, B.W. Van Tassell, and G.G. Biondi-Zoccai Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events BioDrugs 26 2012 217 233
6. A. Abbate, F. Salloum, E. Vecile, A. Das, N. Hoke, S. Straino, G.G.L. Biondi-Zoccai, J. Houser, I. Qureshi, E. Ownby, E. Gustini, L. Biasucci, A. Severino, M. Capogrossi, G. Vetrovec, F. Crea, A. Baldi, R. Kukreja, and A. Dobrina Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction Circulation 117 2008 2670 2683
7. B.W. Van Tassell, A. Varma, F.N. Salloum, A. Das, I.M. Seropian, S. Toldo, L. Smithson, N.N. Hoke, V.Q. Chau, R. Robati, and A. Abbate Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice J Cardiovasc Pharmacol 55 2010 117 122
8. A. Abbate, B.W. Van Tassell, I.M. Seropian, S. Toldo, R. Robati, A. Varma, F.N. Salloum, L. Smithson, and C.A. Dinarello Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse Eur J Heart Fail 12 2010 319 322
9. A. Abbate, M.C. Kontos, J.D. Grizzard, G.G. Biondi-Zoccai, B.W. Van Tassell, R. Robati, L.M. Roach, R.A. Arena, C.S. Roberts, A. Varma, C.C. Gelwix, F.N. Salloum, A. Hastillo, C.A. Dinarello, G.W. Vetrovec VCU-ART Investigators Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] pilot study) Am J Cardiol 105 2010 1371 1377
10. A. Saraste, S. Nekolla, and M. Schwaiger Contrast-enhanced magnetic resonance imaging in the assessment of myocardial infarction and viability J Nucl Cardiol 15 2008 105 117
11. S. Orn, C. Manhenke, T. Ueland, J. Dams, T. Mollnes, T. Edvardsen, P. Aukrust, and K. Dickstein C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction Eur Heart J 30 2009 1180 1186
12. P. Théroux, P.W. Armstrong, K.W. Mahaffey, J.S. Hochman, K.J. Malloy, S. Rollins, J.C. Nicolau, J. Lavoie, T.M. Luong, J. Burchenal, and C.B. Granger Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial Eur Heart J 26 2005 1964 1970
13. D.A. Morrow, E.M. Antman, A. Charlesworth, R. Cairns, S.A. Murphy, J.A. de Lemos, R.P. Giugliano, C.H. McCabe, and E. Braunwald TIMI risk score for ST-elevation myocardial infarction: a convenient bedside, clinical score for risk assessment at presentation Circulation 102 2000 2031 2037
14. T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon III, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr., K. Taubert, R.P. Tracy, F. Vinicor, Centers for Disease Control and Prevention, and American Heart Association Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
15. L.M. Biasucci, G. Liuzzo, R.L. Grillo, G. Caligiuri, A.G. Rebuzzi, A. Buffon, F. Summaria, F. Ginnetti, G. Fadda, and A. Maseri Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability Circulation 99 1999 855 860
16. CAPRICORN Investigators Effects of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial Lancet 357 2001 1385 1390
17. R.N. Doughty, G.A. Whalley, H.A. Walsh, G.D. Gamble, J. López-Sendón, N. Sharpe CAPRICORN Echo Substudy Investigators Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy Circulation 109 2004 201 206
18. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
19. R.A. Weir, P.B. Mark, C.J. Petrie, S. Clements, T. Steedman, I. Ford, L.L. Ng, I.B. Squire, G.S. Wagner, J.J. McMurray, and H.J. Dargie Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157 2009 1088 1096
20. D. Furst Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis Clin Ther 26 2004 1960 1975